ApprovedFDA approval

Trutakna (atacicept-vymj)

Vera Therapeutics (VERA)

Marketer take

Joins a fast-moving IgA nephropathy market (Filspari, Vanrafia, Fabhalta, Tarpeyo) and faces Vertex's povetacicept decision on Nov 30, 2026, so nephrology teams need sharp differentiation.

Sponsor company
Vera Therapeutics (VERA)
Indication
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression
Therapeutic area
Nephrology
Event
FDA approval
Date
Jul 7, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move